Cargando…

Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients

Introduction. Antibiotic treatment regimens against Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients often include aminoglycoside antibiotics that may cause chronic renal failure after repeated courses. Aminoaciduria is an early marker of acute aminoglycoside-induced renal tubu...

Descripción completa

Detalles Bibliográficos
Autores principales: Stehling, Florian, Büscher, Rainer, Grosse-Onnebrink, Jörg, Hoyer, Peter F., Mellies, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241496/
https://www.ncbi.nlm.nih.gov/pubmed/28133546
http://dx.doi.org/10.1155/2017/2602653
_version_ 1782496193273659392
author Stehling, Florian
Büscher, Rainer
Grosse-Onnebrink, Jörg
Hoyer, Peter F.
Mellies, Uwe
author_facet Stehling, Florian
Büscher, Rainer
Grosse-Onnebrink, Jörg
Hoyer, Peter F.
Mellies, Uwe
author_sort Stehling, Florian
collection PubMed
description Introduction. Antibiotic treatment regimens against Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients often include aminoglycoside antibiotics that may cause chronic renal failure after repeated courses. Aminoaciduria is an early marker of acute aminoglycoside-induced renal tubular dysfunction. We hypothesized that urinary amino acid reabsorption is decreased after repeated once-daily tobramycin therapies. Methods. In this prospective cross-sectional study creatinine clearance was estimated by the Schwartz and the Cockcroft-Gault formula. Tubular amino acid reabsorption was determined by ion exchange chromatography in 46 patients with CF who received multiple tobramycin courses (6.3 ± 10.1 (1–57)) in a once-daily dosing regimen and 10 who did not. Results. Estimated creatinine clearance employing the Cockcroft-Gault was mildly reduced in 17/46 (37%) of the patients who received tobramycin and 5/10 (50%) of the patients who did not but in none using the Schwartz formula. No association with lifetime tobramycin courses was found. Tubular amino acid reabsorption was not influenced by the amount of once-daily tobramycin courses. Conclusion. Clinically not significant reduction of eCCL occurred in a minority of CF patients. However, chronic tubular dysfunction was not present in patients with CF repeatedly treated with tobramycin in the once-daily dosing scheme.
format Online
Article
Text
id pubmed-5241496
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-52414962017-01-29 Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients Stehling, Florian Büscher, Rainer Grosse-Onnebrink, Jörg Hoyer, Peter F. Mellies, Uwe Pulm Med Clinical Study Introduction. Antibiotic treatment regimens against Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients often include aminoglycoside antibiotics that may cause chronic renal failure after repeated courses. Aminoaciduria is an early marker of acute aminoglycoside-induced renal tubular dysfunction. We hypothesized that urinary amino acid reabsorption is decreased after repeated once-daily tobramycin therapies. Methods. In this prospective cross-sectional study creatinine clearance was estimated by the Schwartz and the Cockcroft-Gault formula. Tubular amino acid reabsorption was determined by ion exchange chromatography in 46 patients with CF who received multiple tobramycin courses (6.3 ± 10.1 (1–57)) in a once-daily dosing regimen and 10 who did not. Results. Estimated creatinine clearance employing the Cockcroft-Gault was mildly reduced in 17/46 (37%) of the patients who received tobramycin and 5/10 (50%) of the patients who did not but in none using the Schwartz formula. No association with lifetime tobramycin courses was found. Tubular amino acid reabsorption was not influenced by the amount of once-daily tobramycin courses. Conclusion. Clinically not significant reduction of eCCL occurred in a minority of CF patients. However, chronic tubular dysfunction was not present in patients with CF repeatedly treated with tobramycin in the once-daily dosing scheme. Hindawi Publishing Corporation 2017 2017-01-04 /pmc/articles/PMC5241496/ /pubmed/28133546 http://dx.doi.org/10.1155/2017/2602653 Text en Copyright © 2017 Florian Stehling et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Stehling, Florian
Büscher, Rainer
Grosse-Onnebrink, Jörg
Hoyer, Peter F.
Mellies, Uwe
Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients
title Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients
title_full Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients
title_fullStr Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients
title_full_unstemmed Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients
title_short Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients
title_sort glomerular and tubular renal function after repeated once-daily tobramycin courses in cystic fibrosis patients
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241496/
https://www.ncbi.nlm.nih.gov/pubmed/28133546
http://dx.doi.org/10.1155/2017/2602653
work_keys_str_mv AT stehlingflorian glomerularandtubularrenalfunctionafterrepeatedoncedailytobramycincoursesincysticfibrosispatients
AT buscherrainer glomerularandtubularrenalfunctionafterrepeatedoncedailytobramycincoursesincysticfibrosispatients
AT grosseonnebrinkjorg glomerularandtubularrenalfunctionafterrepeatedoncedailytobramycincoursesincysticfibrosispatients
AT hoyerpeterf glomerularandtubularrenalfunctionafterrepeatedoncedailytobramycincoursesincysticfibrosispatients
AT melliesuwe glomerularandtubularrenalfunctionafterrepeatedoncedailytobramycincoursesincysticfibrosispatients